Endometrial Cancer, Risk Factors and Prevention Strategies: Perspectives of Patients and At-Risk Women
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Larissa Meyer, MD
- Phone Number: (713) 745-0973
- Email: lmeyer@mdanderson.org
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- MD Anderson Cancer Center
-
Contact:
- Larissa Meyer Meyer, MD
- Phone Number: 713-745-0973
- Email: lmeyer@mdanderson.org
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Women who present to MD Anderson Cancer Center including MDA Houston Area Locations with a diagnosis of endometrial cancer
- Women who present to MD Anderson Cancer Center including MDA Houston Area Locations with a diagnosis of abnormal uterine bleeding or endometrial hyperplasia
- Women without a diagnosis of endometrial cancer or endometrial hyperplasia
- Women must be at least 18 years or age
- Women must be able to read, write, and speak English
- Women must be willing and able to provide written informed consent
Exclusion Criteria:
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient education
Time Frame: Through study completion; an average of 1 year.
|
To build a patient tool for educating and empowering women to make informed decisions about endometrial cancer prevention strategies.
|
Through study completion; an average of 1 year.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Larissa Meyer, MD, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2023-0443
- NCI-2023-08979 (Other Identifier: NCI-CTRP Clinical Trials Registry)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endometrial Cancer
-
NCT07514078Not yet recruitingTreatment Endometrial Cancer
-
NCT03621904RecruitingEndometrial Cancer Recurrent | Endometrial Cancer Stage III | Endometrial Cancer Stage IV
-
NCT03580421CompletedEndometrial Cancer Stage I | Endometrial Cancer Stage II
-
NCT07062016RecruitingEndometrial Carcinoma | Stage III Endometrial Cancer | Stage IV Endometrial Cancer | Endometrial High Grade Endometrioid Adenocarcinoma | Stage II Endometrial Cancer
-
NCT04917341CompletedGynecologic Cancer | Endometrial Cancer Stage
-
NCT01289041CompletedAdvanced Endometrial Cancer
-
NCT00377520CompletedNeoplasms | Urogenital Neoplasms | Neoplasms by Site | Uterine Neoplasms | Genital Neoplasms, Female | Endometrial Neoplasms | Endometrial Cancer | Endometrium Cancer | Cancer of Endometrium | Cancer of the Endometrium
-
NCT01267357CompletedSerous Papillary Endometrial Cancer
-
NCT00542490CompletedEndometrial Cancer | Papillary Serous | Clear Cell Endometrial Cancer
-
NCT03838861RecruitingEmpowerment, Cervical Cancer, Endometrial Cancer, Follow-up, Nurse-led, PROM
Clinical Trials on Qualitative interviews
-
NCT04536025CompletedAmputation | Prosthesis User
-
NCT03958994CompletedDementia | Falls | Discharge Planning
-
NCT03042715CompletedStem Cell Transplant Complications
-
NCT05646628RecruitingDepression | Chronic Pain
-
NCT05191485RecruitingSurgery | Lung Adenocarcinoma
-
NCT06152679RecruitingBladder Cancer | Bladder Outflow Obstruction
-
NCT06470685Enrolling by invitationGenetic Predisposition to Disease | Prostate Cancer | BRCA Mutation
-
NCT06038877Completed